Ankit Mahadevia

2017

In 2017, Ankit Mahadevia earned a total compensation of $3.2M as Chief Executive Officer at Spero Therapeutics, a 291% increase compared to previous year.

Compensation breakdown

Bonus$114,000
Option Awards$2,679,616
Salary$389,574
Other$1,087
Total$3,184,277

Mahadevia received $2.7M in option awards, accounting for 84% of the total pay in 2017.

Mahadevia also received $114K in bonus, $389.6K in salary and $1.1K in other compensation.

Rankings

In 2017, Ankit Mahadevia's compensation ranked 3,376th out of 14,666 executives tracked by ExecPay. In other words, Mahadevia earned more than 77.0% of executives.

ClassificationRankingPercentile
All
3,376
out of 14,666
77th
Division
Manufacturing
1,158
out of 5,772
80th
Major group
Chemicals And Allied Products
318
out of 2,075
85th
Industry group
Drugs
244
out of 1,731
86th
Industry
Pharmaceutical Preparations
193
out of 1,333
86th
Source: SEC filing on April 27, 2018.

Mahadevia's colleagues

We found three more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2017.

2017

Cristina Larkin

Spero Therapeutics

Chief Operating Officer

2017

Christina Larkin

Spero Therapeutics

Chief Operating Officer

2017

Joel Sendek

Spero Therapeutics

Chief Financial Officer

News

In-depth

You may also like